If all the extra supply from USA fracking caused the price of crude to plummet, what will stop the rest of the world from using fracking to increase the supply of crude even more for many years to come?
realistically, what should we expect for now?
I suggest that before the next CC, we will have a Calcitriol launch and a Triferic agreement with one of the big 4
If we get that, we might hit 52 week highs
I believe that in an earlier conference call this year that Rob indicated that there are 8 major customers that were the target market for Triferic. These 8 customers comprised a large percentage of the market.
Could someone post who those 8 dialysis companies are and how many customers that each of the 8 have. If you also have the total number of dialysis patients that would also be helpful
good point and I would like to hear from a board expert about how profitable Triferic sales will be . People sometimes get so excited about a sales contract, but the real question is how profitable are the sales going to be. I'm not sure with the bundled pricing mechanism. At some point we will know what the margins are, but right now, unless you are an insider, one can only guess
I've been in RMTI for over 3 years now. Regardless of what the pumpers or bashers on this board say, it is a small biotech with its future pretty much tied to Triferic. Triferic gained FDA approval in January (from memory). I know that it takes time to work on contracts, manufacturing, etc. I get it, but the reality is there are only 8 bigger customers with 4 much bigger. Rob started the company but he treats it as his instead of a publicly traded entity. I listened to the CC a couple of times and still am not sure where we stand I was hoping for a lot more detail. I'm still giving Rob the benefit of the doubt, but if we don't get a couple of more Triferic contracts inked and a Calcitriol launch by the next CC, it will be very discouraging.
I agree that Rob should be much more forthcoming in the conference calls. I still don't understand why RMTI has not launched Calcitriol. This is a generic application and it should not be that difficult to produce. It makes me question RMTI's mgmt. ability.
Right now, every thing hinges on Triferic and with the long standing relationship with DaVita, why hasn't a contract been inked? I realize that they are big, but we have known the folks there a long time and DaVita has been around the Triferic story a long time. I hope that some fine contractual points are being ironed out and a contract will be inked soon.
The problem is not 2015. The reason that all the off shore drillers are down is the 2016 and 2017 projected earnings. I'm long and will hold for a rebound, but this could get a lot worse before it gets better. There will need to be more rigs taken out of service for the entire industry. Additionally, I seriously doubt that Thigpen will try to acquire a competitor until he sees the end of the cyclical downturn a lot closer. It is difficult to be a shareholder in anyone in this industry
go back under the rock where you came from. Another idiot for the ignore button
I listened to the CC twice and admit that I am still confused. I posted the Oppenheimer details earlier today. If you read her entire write up, she has uncertainty issues in several places. I still don't understand how profitable with bundled pricing that Triferic will be. Also, what kind of introductory discounts are going to be given? I suppose that we just have to wait. I do think that there will continue to have a lot of price volatility until we get more facts about Triferic sales and profitability
PRICE TARGET CALCULATION
We use a sum-of-the parts analysis to value RMTI shares. Our 12- to 18-month target price of $26 is derived by summing up the following components of its development programs: the estimated risk-adjusted net present value of Triferic at ~$1B (or $20/share), the estimated risk-adjusted NPV of Calcitriol at ~$193M (~$4/share), and the existing business, valued at ~$100M ($2/share).
■ Financing risk: RMTI may need to raise additional capital in the near future, potentially causing dilution for shareholders.
■ Commercialization risks: The market potential and penetration of RMTI's product candidates, especially Triferic and Calcitriol, may not be as large as our projections.
■ High stock price volatility: High stock price volatility is common among developmental companies in the biotechnology sector.
None of your posts have ever contained much content. I will be glad when it hits $14 (if it ever gets there again). You just don't get it. When a company disappoints Wall Street, the stock goes down. Rob has disappointed WS numerous times and there price action today speaks for itself. I'm just waiting for a price bump to dump this garbage. Yes, I'm unhappy at RMTI mgmt. I should have sold my remaining shares at $18 during the last price spike. If we ever get another price spike, I won't make the the same mistake again
I originally purchased my stock over 3 years ago. I sold 1/2 of my shares this Summer for $14 and with the profit I made, my remaining shares are basically free. I like the Triferic story but am not inspired with Rob C. I went to the last annual meeting and was not inspired by him. He is a salesman and he stated as much. There is no reason for Calcitriol to not have launched by now. Triferic will come under Medicare bundling pricing. I don't know how much profit will be generated but this is a company betting heavily on Triferic. If we don't get big profits, the balloon will deflate more. The pumpers on this board don't understand that if you disappoint wall street, your stock price will be punished. There is no reason for Calcitriol to not have launched by now...except for incompetent mgmt.
I'm long the stock but will dump it if we ever get back $14. It displays a volatile chart and I could get a bump up if we get some good news. I'm neither a basher nor pumper. I expect RMTI to deliver and yesterday's CC was weaker than the market was expecting. It is down on pretty heavy volume; so, some bigger players must be selling based on yesterday's CC
Granted that Calcitriol will not be a huge profit driver like Triferic, but it speaks very poorly on Rob's ability to manage a very small company. This is generic Vitamin D and they have talked about launching it for a year, maybe longer. It just makes me question the management at RMTI. I agree that it is complete BS from mgmt. We should have been selling this product by now. I heard some excuse relating to manufacturing problems...very troubling and definitely it does not look RMTI mgmt. look good. I continue to hold, but am happy that I sold 1/2 of my position at $14 earlier in the year. These small biotech companies are very volatile
I'm still holding the stock, but I expected more from the CC yesterday. I still am baffled as to why RMTI has not brought Calcitriol to market after more than 1 year. If it is in fact a manufacturing issue, someone needs to be held accountable. Without Triferic, if you had Calcitriol sales, we would be profitable. I wanted more information on ongoing Triferic pilot programs to be given during the CC. In any event, for the moment, the market price has dropped on pretty heavy volume and it is not a welcome barometer following yesterday's Triferic sales contract announcement.
I hope that RMTI will have good margins for Triferic. Since they still are having trouble bringing Calcitriol to market (after more than a year), everything is riding on Triferic to get to the $20+ price range that a lot of the analysts are targeting. I am hoping that the Oppenheimer analyst comes out with a revised view of 2016 sales, profits and target price. I continue to hold the stock and am looking for more facts to understand what realistic profits that we can expect from RMTI. In the final analysis the eps growth will dive the stock price. I'm still hopeful that Triferic will be a big hit, but today's price action makes me nervous